A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients

• DOI: 10.1002/cpt.1198
• Publication Date: 2018-07-30T10:53:48Z
• Authors: Ida Netterberg; Chi‐Chung Li; Luciana Molinero; Nageshwar Budha; Siddharth Sukumaran; Mark Stroh; E. Niclas Jonsson; Lena E. Friberg
• Keywords: Atezolizumab; Pharmacodynamics

To assess circulating biomarkers as predictors of antitumor response to atezolizumab (anti-programmed death-ligand 1 (PD-L1), Tecentriq) serum pharmacokinetic (PK) and 95 plasma were analyzed in 88 patients with relapsed/refractory non-small cell lung cancer (NSCLC) receiving i.v. q3w (10-20 mg/kg) the PCD4989g phase I clinical trial. Following exploratory analyses, two chosen for further study correlation change tumor size (the sum longest diameter) was assessed a pharmacokinetic/pharmacodynamic (PK/PD) modeling framework. When longitudinal kinetics modeled, shrinkage found significantly correlate area under curve (AUC), baseline factors (metastatic sites, liver metastases, smoking status), relative interleukin (IL)-18 level from at day 21 (RCFBIL-18,d21 ). Although AUC major predictor shrinkage, effect estimated dissipate an average half-life 80 days, whereas RCFBIL-18,d21 seemed relevant duration response.